03:57 AM EDT, 06/16/2025 (MT Newswires) -- Prothena ( PRTA ) said Monday that its partner Roche will advance their investigational drug prasinezumab into phase 3 development as a potential treatment for early-stage Parkinson's disease.

The decision follows data from two phase 2 studies and their ongoing extensions involving over 750 patients that have shown potential clinical efficacy, the company said.

Under an agreement, Roche is responsible for developing and commercializing prasinezumab while paying Prothena ( PRTA ) up to double-digit teen royalties on sales, the company said.